Advisors Capital Management LLC Has $32.39 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Advisors Capital Management LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 6.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 217,536 shares of the company’s stock after buying an additional 14,087 shares during the quarter. Johnson & Johnson accounts for approximately 1.5% of Advisors Capital Management LLC’s investment portfolio, making the stock its 10th largest position. Advisors Capital Management LLC’s holdings in Johnson & Johnson were worth $32,387,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Newfound Research LLC bought a new stake in Johnson & Johnson during the 3rd quarter worth approximately $28,000. Islay Capital Management LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth $42,000. FAI Wealth Management grew its stake in shares of Johnson & Johnson by 45.9% in the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock worth $45,000 after purchasing an additional 101 shares during the last quarter. SeaBridge Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 160.0% in the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after purchasing an additional 200 shares during the last quarter. Finally, HWG Holdings LP bought a new position in Johnson & Johnson during the 2nd quarter worth $49,000. Institutional investors and hedge funds own 67.44% of the company’s stock.

JNJ stock opened at $150.85 on Tuesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24. The company’s 50-day moving average is $145.39 and its 200-day moving average is $146.58. The stock has a market capitalization of $397.12 billion, a PE ratio of 23.72, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.22. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The business had revenue of $21.08 billion for the quarter, compared to the consensus estimate of $20.15 billion. During the same period in the prior year, the business earned $2.12 EPS. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. On average, analysts anticipate that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.01 dividend. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.68%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio is currently 46.54%.

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the sale, the executive vice president now owns 66,658 shares in the company, valued at approximately $10,233,336.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.27% of the company’s stock.

A number of equities research analysts have commented on the company. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. Independent Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the company from $161.00 to $164.00 in a report on Monday, July 20th. Bank of America restated a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 20th. Credit Suisse Group upped their price objective on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday, October 14th. Finally, Stifel Nicolaus downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $164.93.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Story: Why do analysts give a neutral rating?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.